Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses

Abstract The SARS-CoV-2 pandemic has reemphasized the urgent need for broad-spectrum antiviral therapies. We developed a computational workflow using scRNA-Seq data to assess cellular metabolism during viral infection. With this workflow we predicted the capacity of cells to sustain SARS-CoV-2 virio...

Full description

Saved in:
Bibliographic Details
Main Authors: Alina Renz, Mirjam Hohner, Raphaël Jami, Maximilian Breitenbach, Jonathan Josephs-Spaulding, Johanna Dürrwald, Lena Best, Victoria Dulière, Chloé Mialon, Stefanie M. Bader, Georgios Marinos, Nantia Leonidou, Filipe Cabreiro, Marc Pellegrini, Marcel Doerflinger, Manuel Rosa-Calatrava, Andrés Pizzorno, Andreas Dräger, Michael Schindler, Christoph Kaleta
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-025-08148-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850127888453468160
author Alina Renz
Mirjam Hohner
Raphaël Jami
Maximilian Breitenbach
Jonathan Josephs-Spaulding
Johanna Dürrwald
Lena Best
Victoria Dulière
Chloé Mialon
Stefanie M. Bader
Georgios Marinos
Nantia Leonidou
Filipe Cabreiro
Marc Pellegrini
Marcel Doerflinger
Manuel Rosa-Calatrava
Andrés Pizzorno
Andreas Dräger
Michael Schindler
Christoph Kaleta
author_facet Alina Renz
Mirjam Hohner
Raphaël Jami
Maximilian Breitenbach
Jonathan Josephs-Spaulding
Johanna Dürrwald
Lena Best
Victoria Dulière
Chloé Mialon
Stefanie M. Bader
Georgios Marinos
Nantia Leonidou
Filipe Cabreiro
Marc Pellegrini
Marcel Doerflinger
Manuel Rosa-Calatrava
Andrés Pizzorno
Andreas Dräger
Michael Schindler
Christoph Kaleta
author_sort Alina Renz
collection DOAJ
description Abstract The SARS-CoV-2 pandemic has reemphasized the urgent need for broad-spectrum antiviral therapies. We developed a computational workflow using scRNA-Seq data to assess cellular metabolism during viral infection. With this workflow we predicted the capacity of cells to sustain SARS-CoV-2 virion production in patients and found a tissue-wide induction of metabolic pathways that support viral replication. Expanding our analysis to influenza A and dengue viruses, we identified metabolic targets and inhibitors for potential broad-spectrum antiviral treatment. These targets were highly enriched for known interaction partners of all analyzed viruses. Indeed, phenformin, an NADH:ubiquinone oxidoreductase inhibitor, suppressed SARS-CoV-2 and dengue virus replication. Atpenin A5, blocking succinate dehydrogenase, inhibited SARS-CoV-2, dengue virus, respiratory syncytial virus, and influenza A virus with high selectivity indices. In vivo, phenformin showed antiviral activity against SARS-CoV-2 in a Syrian hamster model. Our work establishes host metabolism as druggable for broad-spectrum antiviral strategies, providing invaluable tools for pandemic preparedness.
format Article
id doaj-art-5fc348de31a04dc7ae944f3341da0cf5
institution OA Journals
issn 2399-3642
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Communications Biology
spelling doaj-art-5fc348de31a04dc7ae944f3341da0cf52025-08-20T02:33:32ZengNature PortfolioCommunications Biology2399-36422025-05-018111910.1038/s42003-025-08148-yMetabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA virusesAlina Renz0Mirjam Hohner1Raphaël Jami2Maximilian Breitenbach3Jonathan Josephs-Spaulding4Johanna Dürrwald5Lena Best6Victoria Dulière7Chloé Mialon8Stefanie M. Bader9Georgios Marinos10Nantia Leonidou11Filipe Cabreiro12Marc Pellegrini13Marcel Doerflinger14Manuel Rosa-Calatrava15Andrés Pizzorno16Andreas Dräger17Michael Schindler18Christoph Kaleta19Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), Eberhard Karl University of TübingenInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital TübingenInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital TübingenInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital TübingenResearch Group Medical Systems Biology, Institute of Experimental Medicine, Christian-Albrechts-University Kiel & University Hospital Schleswig HolsteinInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital TübingenResearch Group Medical Systems Biology, Institute of Experimental Medicine, Christian-Albrechts-University Kiel & University Hospital Schleswig HolsteinCIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de LyonCIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de LyonDivision of Infectious Diseases and Immune Defense, The Walter and Eliza Hall Institute of Medical ResearchResearch Group Medical Systems Biology, Institute of Experimental Medicine, Christian-Albrechts-University Kiel & University Hospital Schleswig HolsteinComputational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), Eberhard Karl University of TübingenCologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of CologneDivision of Infectious Diseases and Immune Defense, The Walter and Eliza Hall Institute of Medical ResearchDivision of Infectious Diseases and Immune Defense, The Walter and Eliza Hall Institute of Medical ResearchCIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de LyonCIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de LyonComputational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), Eberhard Karl University of TübingenInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital TübingenResearch Group Medical Systems Biology, Institute of Experimental Medicine, Christian-Albrechts-University Kiel & University Hospital Schleswig HolsteinAbstract The SARS-CoV-2 pandemic has reemphasized the urgent need for broad-spectrum antiviral therapies. We developed a computational workflow using scRNA-Seq data to assess cellular metabolism during viral infection. With this workflow we predicted the capacity of cells to sustain SARS-CoV-2 virion production in patients and found a tissue-wide induction of metabolic pathways that support viral replication. Expanding our analysis to influenza A and dengue viruses, we identified metabolic targets and inhibitors for potential broad-spectrum antiviral treatment. These targets were highly enriched for known interaction partners of all analyzed viruses. Indeed, phenformin, an NADH:ubiquinone oxidoreductase inhibitor, suppressed SARS-CoV-2 and dengue virus replication. Atpenin A5, blocking succinate dehydrogenase, inhibited SARS-CoV-2, dengue virus, respiratory syncytial virus, and influenza A virus with high selectivity indices. In vivo, phenformin showed antiviral activity against SARS-CoV-2 in a Syrian hamster model. Our work establishes host metabolism as druggable for broad-spectrum antiviral strategies, providing invaluable tools for pandemic preparedness.https://doi.org/10.1038/s42003-025-08148-y
spellingShingle Alina Renz
Mirjam Hohner
Raphaël Jami
Maximilian Breitenbach
Jonathan Josephs-Spaulding
Johanna Dürrwald
Lena Best
Victoria Dulière
Chloé Mialon
Stefanie M. Bader
Georgios Marinos
Nantia Leonidou
Filipe Cabreiro
Marc Pellegrini
Marcel Doerflinger
Manuel Rosa-Calatrava
Andrés Pizzorno
Andreas Dräger
Michael Schindler
Christoph Kaleta
Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses
Communications Biology
title Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses
title_full Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses
title_fullStr Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses
title_full_unstemmed Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses
title_short Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses
title_sort metabolic modeling elucidates phenformin and atpenin a5 as broad spectrum antiviral drugs against rna viruses
url https://doi.org/10.1038/s42003-025-08148-y
work_keys_str_mv AT alinarenz metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT mirjamhohner metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT raphaeljami metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT maximilianbreitenbach metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT jonathanjosephsspaulding metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT johannadurrwald metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT lenabest metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT victoriaduliere metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT chloemialon metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT stefaniembader metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT georgiosmarinos metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT nantialeonidou metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT filipecabreiro metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT marcpellegrini metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT marceldoerflinger metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT manuelrosacalatrava metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT andrespizzorno metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT andreasdrager metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT michaelschindler metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses
AT christophkaleta metabolicmodelingelucidatesphenforminandatpenina5asbroadspectrumantiviraldrugsagainstrnaviruses